{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:19:07Z","timestamp":1786997947647,"version":"build-2736575974"},"reference-count":25,"publisher":"Elsevier BV","issue":"41","license":[{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2023,9]]},"DOI":"10.1016\/j.vaccine.2023.08.030","type":"journal-article","created":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T07:51:00Z","timestamp":1692690660000},"page":"5974-5978","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen\u00ae) vaccination on antibody titers; a japanese cross-sectional study"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8926-7320","authenticated-orcid":false,"given":"Yohei","family":"Maki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5579-0773","authenticated-orcid":false,"given":"Naoki","family":"Edo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Mizuguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikihito","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0608-7170","authenticated-orcid":false,"given":"Masato","family":"Kitano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etsuko","family":"Kitagami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morichika","family":"Osa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Yamamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takunori","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5684-6051","authenticated-orcid":false,"given":"Takahiro","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akihiko","family":"Kawana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4026-7506","authenticated-orcid":false,"given":"Yoshifumi","family":"Kimizuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2023.08.030_b0005","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1093\/oxfordjournals.aje.a114093","article-title":"Frequency of illness associated with epidemic hepatitis A virus infections in adults","volume":"122","author":"Lednar","year":"1985","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.vaccine.2023.08.030_b0010","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0891-5520(05)70123-9","article-title":"Hepatitis A","volume":"14","author":"Kemmer","year":"2000","journal-title":"Infect Dis Clin North Am"},{"key":"10.1016\/j.vaccine.2023.08.030_b0015","doi-asserted-by":"crossref","first-page":"6653","DOI":"10.1016\/j.vaccine.2010.08.037","article-title":"Hepatitis A virus seroprevalence by age and world region, 1990 and 2005","volume":"28","author":"Jacobsen","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.030_b0020","doi-asserted-by":"crossref","unstructured":"Nelson NP, Weng MK, Hofmeister MG, Moore KL, Doshani M, Kamili S, et al. Prevention of hepatitis A virus infection in the United States: Recommendations of the Advisory Committee on Immunization Practices, 2020. MMWR Recomm Rep. 2020;69:1\u201338. https:\/\/doi.org\/10.15585\/mmwr.rr6905a1 [published correction appears in MMWR Morb Mortal Wkly Rep. 2021;70:294. https:\/\/doi.org\/10.15585\/mmwr.mm7008a5].","DOI":"10.15585\/mmwr.rr6905a1"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.08.030_b0025","article-title":"Clinical assessment of the safety and efficacy of an inactivated hepatitis A vaccine: Rationale and summary of findings","volume":"10","author":"Andr\u00e9","year":"1992","journal-title":"Vaccine"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.08.030_b0030","article-title":"Reactogenicity and immunogenicity of inactivated hepatitis A vaccines","volume":"10","author":"Just","year":"1992","journal-title":"Vaccine"},{"issue":"3","key":"10.1016\/j.vaccine.2023.08.030_b0035","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1093\/infdis\/171.3.676","article-title":"Immunogenicity of an inactivated hepatitis A vaccine in alaska native children and native and non-native adults","volume":"171","author":"Mcmahon","year":"1995","journal-title":"J Infect Dis"},{"issue":"Suppl 1","key":"10.1016\/j.vaccine.2023.08.030_b0040","article-title":"Safety and immunogenicity of an inactivated hepatitis A vaccine in preschool children","volume":"171","author":"Balcarek","year":"1995","journal-title":"J Infect Dis"},{"issue":"2","key":"10.1016\/j.vaccine.2023.08.030_b0045","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1097\/01.inf.0000253253.85640.cc","article-title":"Immunogenicity of an inactivated hepatitis A vaccine in infants and young children","volume":"26","author":"Bell","year":"2007","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2023.08.030_b0050","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.vaccine.2013.10.088","article-title":"Model based estimates of long-term persistence of inactivated hepatitis A vaccine-induced antibodies in adults","volume":"32","author":"Hens","year":"2014","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.030_b0055","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1016\/j.vaccine.2015.07.008","article-title":"Long-term antibody persistence after vaccination with a 2-dose Havrix (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions","volume":"33","author":"Theeten","year":"2015","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2023.08.030_b0060","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1111\/hiv.12424","article-title":"British HIV Association guidelines on the use of vaccines in HIV-positive adults 2015","volume":"17","author":"Geretti","year":"2016","journal-title":"HIV Med"},{"issue":"4","key":"10.1016\/j.vaccine.2023.08.030_b0065","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1111\/jam.13242","article-title":"Efficacy of domestic cooking inactivation of human hepatitis A virus in experimentally infected manila clams (Ruditapes philippinarum)","volume":"121","author":"Pascoli","year":"2016","journal-title":"J Appl Microbiol"},{"key":"10.1016\/j.vaccine.2023.08.030_b0070","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.3390\/v13101900","article-title":"Hepatitis A: Epidemiology, high-risk groups, prevention and research on antiviral treatment","volume":"13","author":"Migueres","year":"2021","journal-title":"Viruses"},{"key":"10.1016\/j.vaccine.2023.08.030_b0075","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/oxfordjournals.bmb.a072410","article-title":"Fulminant viral hepatitis","volume":"46","author":"Fagan","year":"1990","journal-title":"Br Med Bull"},{"issue":"2","key":"10.1016\/j.vaccine.2023.08.030_b0080","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.jiac.2019.08.010","article-title":"Hepatitis A virus-associated fulminant hepatitis with human immunodeficiency virus coinfection","volume":"26","author":"Maki","year":"2020","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.vaccine.2023.08.030_b0085","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1038\/s41598-018-37349-1","article-title":"Very low prevalence of anti-HAV in Japan: High potential for future outbreak","volume":"9","author":"Yamamoto","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.vaccine.2023.08.030_b0090","unstructured":"World Health Organization. Wkly Epidemiol Rec. 2022;97:493\u2013512, https:\/\/www.who.int\/publications\/i\/item\/who-wer9740-493-512."},{"key":"10.1016\/j.vaccine.2023.08.030_b0095","doi-asserted-by":"crossref","first-page":"119","DOI":"10.7883\/yoken1952.40.119","article-title":"Seroepidemiology of hepatitis A virus in Japan","volume":"40","author":"Taylor-Wiedeman","year":"1987","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2023.08.030_b0100","doi-asserted-by":"crossref","first-page":"123","DOI":"10.7883\/yoken1952.50.123","article-title":"The latest seroepidemiological pattern of hepatitis A in Japan","volume":"50","author":"Kiyohara","year":"1997","journal-title":"Jpn J Med Sci Biol"},{"key":"10.1016\/j.vaccine.2023.08.030_b0105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1348-0421.2007.tb03900.x","article-title":"Shifting seroepidemiology of hepatitis A in Japan, 1973\u20132003","volume":"51","author":"Kiyohara","year":"2007","journal-title":"Microbiol Immunol"},{"issue":"6","key":"10.1016\/j.vaccine.2023.08.030_b0110","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/hepr.13314","article-title":"Outbreak of hepatitis A linked to European outbreaks among men who have sex with men in Osaka, Japan, from March to July 2018","volume":"49","author":"Tanaka","year":"2019","journal-title":"Hepatol Res"},{"key":"10.1016\/j.vaccine.2023.08.030_b0115","unstructured":"Advisory Committee on Immunization Practices (ACIP), Fiore AE, Wasley A, Bell BP. Prevention of hepatitis A through active or passive immunization: Recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2006;55:1\u201323, https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/rr5507a1.htm."},{"key":"10.1016\/j.vaccine.2023.08.030_b0120","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1016\/j.vaccine.2017.10.002","article-title":"Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix\u00ae) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen\u00ae) for Japanese travelers to endemic countries","volume":"35","author":"Fukushima","year":"2017","journal-title":"Vaccine"},{"issue":"Suppl 3","key":"10.1016\/j.vaccine.2023.08.030_b0125","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0264-410X(02)00166-4","article-title":"Aluminum salts in vaccines\u2013US perspective","volume":"20","author":"Baylor","year":"2002","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009623?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X23009623?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T11:31:49Z","timestamp":1759404709000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X23009623"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9]]},"references-count":25,"journal-issue":{"issue":"41","published-print":{"date-parts":[[2023,9]]}},"alternative-id":["S0264410X23009623"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of frequency and duration of freeze-dried inactivated tissue culture hepatitis A vaccine (Aimmugen\u00ae) vaccination on antibody titers; a japanese cross-sectional study","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2023.08.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}